NCNicholas Carlson

Nicholas Carlson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicholas Carlson has a total of 174 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Albuminuria predicts diabetic retinopathy and consequences of polyneuropathy in individuals with type 2 diabetes and chronic kidney disease: an observational nationwide Danish cohort study

    by Clara Sophie Turner, Mads Hornum, Ellen Linnea Freese Ballegaard, Nicholas Carlson, Steffen Heegaard, Thomas P. Almdal, Mikkel Porsborg Andersen, Christian Torp-Pedersen, Dea H. Kofod

  • Workforce Detachment in Persons with CKD

    by Rasmus Rørth, Milos M. Koch, Thomas A. Gerds, Nicholas Carlson, Peter Rossing, Thomas Kumler, Christian Torp-Pedersen, Lars Køber, Glenn M. Chertow

    Key Points: In this study, we identified individuals in the workforce with estimated kidney function based on sequential serum creatinine measurements. Individuals with CKD were more likely to experience workforce detachment. The risk of workforce detachment was graded according to CKD severity. These findings were persistent irrespective of age, sex, diabetes status, and level of education. Background: Impaired kidney function is associated with mortality, cardiovascular events, and hospitalization as well as diminished functional capacity and health-related quality of life. We hypothesized that kidney function would be linked to employment status, which itself is closely linked to financial stability, physical and mental health, and personal identity. Methods: By the use of weekly updated information of patients' occupational status, combined with laboratory data and nationwide registries on hospitalizations and deaths, we estimated kidney function in a working age population (18–60 years) to examine the absolute risk of workforce detachment by CKD status and CKD stage using the Aalen-Johansen estimator accounting for competing risks of retirement, and death. Results: We identified 12,704 individuals with CKD and 68,938 matched individuals without CKD in the workforce at index date. Persons with CKD had a higher absolute risk of workforce detachment (1-year absolute risk: 9% versus 5%, P < 0.001); the absolute risk was higher with more advanced CKD: (1-year absolute risk: eGFR >60 ml/min per 1.73 m 2 =5%; CKD stages G3a=8%, G3b=12%, G4=14%, and G5=20%). Older age, female sex, diabetes, and lower level of education were associated with higher likelihood of workforce detachment. Findings related to kidney function were persistent across all subgroups examined. Conclusions: Persons with CKD were significantly more likely to experience workforce detachment than persons with normal or near normal kidney function. These data highlight another, less well-documented burden of CKD, highlighting the urgency to develop and disseminate early detection and treatment interventions.


  • COVID-19 Vaccination and Kidney Disease

    by Nicholas Carlson, Felix Michalik, Thomas Gerds, Ellen Freese Ballegaard, Morten Buus Jørgensen, Karl Emil Nelveg-Kristensen, Pascal Geldsetzer, Mads Hornum, Bo Feldt-Rasmussen, Christian Torp-Pedersen

    Background Benefit of SARS-CoV-2 vaccinations to reduce the risk of infection and subsequent outcomes in patients with impaired kidney function beyond end-stage kidney disease (ESKD) remains uncertain. Objectives To evaluate the vaccination effect on rates of SARS-CoV-2 infection and subsequent risk of 30-day mortality outcomes in patients with kidney disease. Methods Population-based retrospective cohort on nationwide data from multiple national health care registers between February 2021 and June 2022. All vaccine uptake and efficacy were evaluated in granular eGFR categories with comparison of age- and gender-standardized rates of SARS-CoV-2 infection and subsequent risks of 30-day mortality between unvaccinated, vaccinated, and booster-vaccinated persons. Results Based on a population of 982,047 adults with kidney disease, a total of 359,428 SARS-CoV-2 infections (Alpha: n = 7861, Delta: n = 27,868, Omicron: n = 323,699) were identified. Vaccination and booster vaccination were associated with benefits on rates of SARS-CoV-2 infection and subsequent 30-day mortality, with age- and gender-standardized rate ratios for SARS-CoV-2 infection of 0.24 (95% CI 0.21–0.28), 0.33 (95% CI 0.22–0.50), 0.32 (95% CI 0.19–0.54), 0.91 (95% CI 0.32–2.58), and 0.24 (95% CI 0.08–0.73) and age- and gender-standardized 30-day mortality differences of −1.5 (95% CI −1.7, −1.2), −5.8 (95% CI −7.1, −4.5), −12.4 (95% CI −15.3, −9.5), −16.9 (95% CI −21.9, −11.8), and −10.7 (95% CI −16.6, −4.8) for booster vaccinations compared with no vaccination for eGFR ≥ 60 mL/min/1.73 m2, 45–59 mL/min/1.73 m2, 30–44 mL/min/1.73 m2, and < 30 mL/min/1.73 m2 and dialysis, respectively. Conclusions Vaccination and booster vaccination against SARS-CoV-2 were associated with benefits on rates of SARS-CoV-2 infections and associated 30-day mortality risk irrespective of kidney function.

  • Open Access

    Kidney Status and Events Preceding Death in Heart Failure: A Real-world Nationwide Study

    by Deewa Zahir Anjum, Caroline Hartwell Garred, Nicholas Carlson, Emil Fosbol, Mariam Elmegaard, Pardeep S. Jhund, John J.V. McMurray, Mark C. Petrie, Lars Kober, Morten Schou

    Background Chronic kidney disease (CKD) is a frequent comorbidity in heart failure (HF) patients, affecting prognosis and mortality. This study investigates the relationship between kidney function and adverse kidney events preceding death in HF patients. Methods We analyzed registry data of HF patients who died between 2014 and 2021, with at least one year of HF diagnosis. Adverse kidney events, including acute kidney injury (AKI) and end- stage kidney disease (ESKD), were assessed. Patients were grouped by estimated glomerular filtration rate (eGFR) one year before death: eGFR≥60, eGFR 30-59, and eGFRResults Among 36,435 HF patients who died, 37% had eGFR≥60, 46% had eGFR 30-59, and 17% had eGFRConclusions In HF patients, AKI and ESKD are common in the last year of life, particularly in those with lower baseline eGFR, with kidney decline accelerating in the final months.

  • Prevalence and prognostic relevance of electrocardiographic abnormalities among patients with ANCA-associated vasculitis

    by Louis Nygaard, Caroline Hundborg Liboriussen, Nicholas Carlson, Karl Emil Nelveg-Kristensen, Salome Kristensen, Mikkel Porsborg Andersen, Helle Collatz Christensen, Kristian Kragholm, Claus Graff, Christian Torp-Pedersen, et al.

    Objectives: Current guidelines provide limited evidence for cardiovascular screening in ANCA-associated vasculitis (AAV). This study aimed to investigate the prevalence of ECG abnormalities and associations between no, minor or major ECG abnormalities with cardiovascular mortality in AAV patients compared with matched controls. Methods: Using a risk-set matched cohort design, patients diagnosed with granulomatosis with polyangiitis or microscopic polyangiitis with digital ECGs were identified from Danish registers from 2000 to 2021. Patients were matched 1:3 to controls without AAV on age, sex and year of ECG measurement. Associated hazards of cardiovascular mortality according to ECG abnormalities were assessed in Cox regression models adjusted for age, sex and comorbidities, with subsequent computation of 5-year risk of cardiovascular mortality standardized to the age- and sex-distribution of the sample. Results: A total of 1431 AAV patients were included (median age: 69 years, 52.3% male). Median follow-up was 4.8 years. AAV was associated with a higher prevalence of left ventricular hypertrophy (17.5% vs 12.5%), ST-T deviations (10.1% vs 7.1%), atrial fibrillation (9.6% vs 7.5%) and QTc prolongation (5.9% vs 3.6%). Only AAV patients with major ECG abnormalities demonstrated a significantly elevated risk of cardiovascular mortality [HR 1.99 (1.49–2.65)] compared with controls. This corresponded to a 5-year risk of cardiovascular mortality of 19.14% (16–22%) vs 9.41% (8–11%). Conclusion: Patients with AAV demonstrated a higher prevalence of major ECG abnormalities than controls. Notably, major ECG abnormalities were associated with a significantly increased risk of cardiovascular mortality. These results advocate for the inclusion of ECG assessment into routine clinical care for AAV patients.


  • Acute Myocardial Infarction and Chronic Kidney Disease

    by Ellen Linnea Freese Ballegaard, Erik Lerkevang Grove, Anne-Lise Kamper, Bo Feldt-Rasmussen, Gunnar Gislason, Christian Torp-Pedersen, Nicholas Carlson

    Key Points: Retrospective study of guideline-directed management of myocardial infarction in patients with and without CKD from 2010 to 2022. CKD was associated with lower rate of guideline-directed management and worse prognosis. Uptake of guideline-directed management increased and prognosis improved in both groups during the study period. Background: CKD is present in >30% of patients with acute myocardial infarction (MI) and has been associated with lower rates of guideline-directed management and worse prognosis. We investigated the use of guideline-directed management and mortality risk in patients with and without CKD. Methods: A nationwide cohort study based on health care registers encompassing all patients ≥18 years hospitalized with first-time MI in Denmark from 2010 to 2022 was conducted. CKD was defined as an eGFR 2. Probability of guideline-directed management and risk of all-cause mortality in patients with and without CKD were calculated from adjusted multivariable logistic and Cox regression models with probabilities and risks standardized to the distribution of confounders in the population. Results: In total, we identified 21,009 patients who met eligibility criteria. The median age was 72 years, and 61% of patients were male; the median eGFR was 82 ml/min per 1.73 m2, and 21% of patients had CKD. The 30-day probabilities of coronary angiography and revascularization were 71% (95% confidence interval [CI], 69% to 72%) and 78% (95% CI, 77% to 79%), P < 0.001 and 52% (95% CI, 50% to 54%) and 58% (95% CI, 58% to 59%), P < 0.001, in patients with and without CKD, respectively. Probabilities increased during the study period (P for trend 0.05, 0.03, 0.02, and 0.03, respectively). In patients with and without CKD, the probability of dual antiplatelet therapy was 67% (95% CI, 65% to 68%) and 70% (95% CI, 69% to 71%), P = 0.001, whereas the probability of lipid-lowering treatment was 76% (95% CI, 75% to 78%) and 82% (95% CI, 81% to 83%), P < 0.001, respectively. The associated 1-year mortality was 21% (95% CI, 20% to 22%) and 16.4% (95% CI, 16% to 17%) in patients with and without CKD, respectively. with decreasing mortality rates in both groups during the study period (P for trend 0.03 and 0.01). Conclusions: Although survival after MI improved for all patients, CKD continued to be associated with lower use of guideline-directed management and higher mortality.


  • Open Access

    Temporal Trends in the Initiation of Dialysis Among Patients With Heart Failure With or Without Diabetes: A Nationwide Study From 2002 to 2016

    by Pauline Knigge, Sørine Lundberg, Jarl E. Strange, Mariam E. Malik, Nina Nouhravesh, Andrea K. Wagner, Gunnar Gislason, Emil L. Fosbøl, Nicholas Carlson, Deewa Zahir, et al.

    Background: The incidence and distribution of acute and chronic dialysis among patients with heart failure (HF), stratified by diabetes, remain uncertain. We hypothesized that with improved survival and rising comorbidities, the demand for dialysis would increase over time. Methods and Results: Patients with incident HF, aged 18 to 100 years, between 2002 and 2016, were identified using Danish nationwide registers. Primary outcomes included acute and chronic dialysis initiation, HF‐related hospitalization, and all‐cause mortality. These outcomes were assessed in 2002 to 2006, 2007 to 2011, and 2012 to 2016, stratified by diabetes. We calculated incidence rates (IRs) per 1000 person‐years and hazard ratios (HR) using multivariable Cox regression. Of 115 533 patients with HF, 2734 patients received acute dialysis and 1193 patients received chronic dialysis. The IR was 8.0 per 1000 and 3.5 per 1000 person‐years for acute and chronic dialysis, respectively. Acute dialysis rates increased significantly among patients with diabetes over time, while no significant changes occurred in those without diabetes, chronic dialysis, HF‐related hospitalization, or overall mortality. Diabetes was associated with significantly higher HRs of acute and chronic dialysis, respectively, compared with patients without diabetes (HR, 2.07 [95% CI, 1.80–2.39] and 2.93 [95% CI, 2.40–3.58] in 2002 to 2006; HR, 2.45 [95% CI, 2.14–2.80] and 2.86 [95% CI, 2.32–3.52] in 2007 to 2011; and 2.69 [95% CI, 2.33–3.10] and 3.30 [95% CI, 2.69–4.06] in 2012 to 2016). Conclusions: The IR of acute and chronic dialysis remained low compared with HF‐related hospitalizations and mortality. Acute dialysis rates increased significantly over time, contrasting no significant trends in other outcomes. Diabetes exhibited over 2‐fold increased rates of the outcomes. These findings emphasize the importance of continued monitoring and renal care in patients with HF, especially with diabetes, to optimize outcomes and prevent adverse events.


  • Open Access

    Coronary angiography in patients with kidney dysfunction and myocardial injury: A retrospective cohort study on management of myocardial injury in hospitalized patients with kidney disease

    by Emilie Illum, Dea Haagensen Kofod, Ellen Freese Ballegaard, Karl Emil Nelveg-Kristensen, Mads Hornum, Morten Schou, Christian Torp-Pedersen, Gunnar Gislason, Jens Flensted Lassen, Nicholas Carlson


  • Open Access

    Impact of Acute Kidney Injury After Transcatheter Aortic Valve Replacement: A Nationwide Study

    by Jeppe Kofoed Petersen, Lauge Østergaard, Nicholas Carlson, Lucas Grove Vejlstrup Bager, Jarl E. Strange, Morten Schou, Lars Køber, Emil Loldrup Fosbøl

    Background: In patients undergoing transcatheter aortic valve replacement (TAVR), the impact of acute kidney injury (AKI) on the prognosis and especially on future kidney function has been sparsely examined, and data from large cohorts are warranted. Methods and Results: With Danish nationwide registries, we identified all patients undergoing TAVR from 2014 to 2021 with no previous dialysis treatment. According to 2 plasma creatinine samples, we identified those suffering a postprocedural AKI within 21 days after TAVR. With 1 year of follow‐up, we compared the associated rates of dialysis treatment and death between patients with and without an AKI using multivariable Cox analysis. Finally, according to the lowest recorded creatinine sample, we assessed the kidney function among AKI survivors between 90 and 180 days after the index date. We identified 4091 TAVRs: 193 (4.7%) with AKI (55.4% men; median age, 82 years) and 3898 (95.3%) without AKI (57.0% men; median age, 81 years). Compared with those without AKI, patients with AKI showed increased associated 1‐year rates of dialysis treatment (hazard ratio [HR], 7.20 [95% CI, 4.10–12.66]) and death (HR, 2.39 [95% CI, 1.59–3.58]). After 6 months, 74% of AKI survivors had complete kidney recovery, 14.7% had incomplete kidney recovery, 6.3% failed to recover, and 5.1% were on dialysis treatment. Conclusions: We identified that AKI after TAVR was associated with an increased rate of future dialysis treatment and all‐cause death. Among survivors, 74% had complete kidney recovery within 6 months.


  • Increased risk of cardiovascular disease preceding diagnosis of incident ANCA-associated vasculitis: a Danish nationwide study

    by Louis Nygaard, Christoffer Polcwiartek, Karl Emil Nelveg-Kristensen, Nicholas Carlson, Salome Kristensen, Christian Torp-Pedersen, DANVAS Investigators, Jon Waarst Gregersen

    Objective: To examine whether patients with ANCA-associated vasculitis (AAV) have an increased risk of cardiovascular disease in the months prior to diagnosis of AAV. Methods: Using a nested case–control framework, patients with granulomatosis with polyangiitis and microscopic polyangiitis were identified through the Danish Nationwide Registries from 1996 to 2021 and matched 1:3 with age- and sex-matched controls without AAV. Each control was assigned the same index date (date of AAV diagnosis) as their corresponding case. Conditional logistic regression was used to compute adjusted hazard ratios (HRs) for major adverse cardiovascular events (MACE), ischaemic heart disease, coronary angiogram, heart failure, venous thromboembolism, atrial fibrillation, ischaemic stroke, pericarditis and ventricular arrhythmias/implantable cardioverter defibrillator implantation/cardiac arrest (VA/ICD/CA) within 12 months, 6 months, 3 months, 2 months and 1 month before index date. Results: A total of 2371 patients with AAV (median age 63 years, 53.7% male) were matched with 7113 controls. The prevalence of any cardiovascular outcome and MACE within 12 months preceding index date were 10.3% and 2.4% for AAV, compared with 3.8% [HR 3.05 (95% CI 2.48–3.75)] and 1.3% [HR 1.98 (95% CI 1.39–2.82)] of controls. The risk of cardiovascular outcomes was similarly increased in temporal proximity to the diagnosis, with the highest HR at 1 month prior to index date: any cardiovascular outcome [HR 10.73 (95% CI 7.05–16.32)] and MACE [HR 5.78 (95% CI 2.67–12.52)]. In individual analysis, a significantly higher rate was observed for all outcomes (excluding VA/ICD/CA). Conclusions: AAV disease is associated with an increased risk of cardiovascular disease in the months preceding diagnosis, which underlines the importance of early clinical vigilance towards cardiovascular disease.